
ICPT
Healthcare · Biotechnology · $794.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · -325.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2023 | After the close | -0.44 | 0.08 | +118.2% |
| Aug 2, 2023 | Before the open | -0.51 | -0.14 | +72.5% |
| Apr 27, 2023 | Before the open | -0.65 | -0.77 | -18.5% |
| Mar 2, 2023 | Before the open | -0.16 | -0.50 | -212.5% |
| Nov 1, 2022 | Before the open | 4.61 | 7.80 | +69.2% |
| Aug 3, 2022 | Before the open | -0.49 | -0.68 | -38.8% |
| May 6, 2022 | After the close | -0.90 | -0.58 | +35.6% |
| Mar 2, 2022 | Before the open | -1.10 | -1.23 | -11.8% |
| Nov 3, 2021 | Before the open | -1.09 | -0.63 | +42.2% |
| Jul 29, 2021 | Before the open | -1.22 | -0.33 | +73.0% |
| May 6, 2021 | Before the open | -1.44 | -1.22 | +15.3% |
| Feb 25, 2021 | Before the open | -1.47 | -1.58 | -7.5% |
| Nov 9, 2020 | Before the open | -1.93 | -1.61 |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for…
| +16.6% |
| Aug 10, 2020 | Before the open | -2.92 | -1.92 | +34.2% |
| May 11, 2020 | Before the open | -2.90 | -2.86 | +1.4% |
| Feb 25, 2020 | Before the open | -2.67 | -2.99 | -12.0% |
| Nov 5, 2019 | Before the open | -2.43 | -2.59 | -6.6% |
| Aug 7, 2019 | Before the open | -2.60 | -2.28 | +12.3% |
| May 8, 2019 | Before the open | -2.52 | -3.03 | -20.2% |
| Feb 28, 2019 | Before the open | -2.49 | -2.97 | -19.3% |
| Oct 31, 2018 | Before the open | -2.56 | -2.18 | +14.8% |
| Aug 2, 2018 | Before the open | -2.84 | -2.58 | +9.2% |
| May 8, 2018 | Before the open | -3.38 | -3.22 | +4.7% |
| Feb 14, 2018 | Before the open | -3.55 | -4.43 | -24.8% |